0001415889-24-015041.txt : 20240531 0001415889-24-015041.hdr.sgml : 20240531 20240531161825 ACCESSION NUMBER: 0001415889-24-015041 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240529 FILED AS OF DATE: 20240531 DATE AS OF CHANGE: 20240531 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stalfort John A III CENTRAL INDEX KEY: 0001709418 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 241009894 MAIL ADDRESS: STREET 1: C/O ACUMEN PHARMACEUTICALS, INC. STREET 2: 427 PARK STREET CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 FORMER NAME: FORMER CONFORMED NAME: Stalfort Sean DATE OF NAME CHANGE: 20170615 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 form4-05312024_040510.xml X0508 4 2024-05-29 0001806310 Taysha Gene Therapies, Inc. TSHA 0001709418 Stalfort John A III C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, SUITE 1430 DALLAS TX 75247 true false false false 0 Common Stock 2024-05-29 4 A 0 49220 0 A 1098601 D Common Stock 884290 I See footnote Stock Option (right to buy) 3.17 2024-05-29 4 A 0 98440 0 A 2034-05-29 Common Stock 98440 98440 D Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018. The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date. /s/ Kamran Alam, Attorney-in-Fact 2024-05-31